Income Statement Presentation 2023

2022: Group Core cost of sales (COS) Increase due to volume growth, partially offset by the base effect of the 2021 incremental production costs for Ronapreve & AT-527 CHFM 18'355 18'141 -613 17'528 +827 COS as % of group sales 28.9% 27.9% Underlying COS increase by +5% vs. +6% volume increase 28.6% COS 2021 Incremental production costs Normalized Underlying COS COS COS growth from 2022 for Ronapreve & 2021 adjusted base AT-527 All at CER=Constant Exchange Rates; COS-Cost of Sales Roche 54

View entire presentation